Posted by Michael Wonder on 18 Feb 2022
OSE Immunotherapeutics is pleased to announce that Veloxis Pharmaceuticals, its partner in transplantation, has obtained FDA fast track designation for CD28 antagonist VEL-101/FR104
17 February 2022 - OSE Immunotherapeutics today announced that Veloxis Pharmaceuticals has obtained fast track designation from the U.S. FDA for VEL-101/FR104, a novel investigational maintenance immunosuppressive agent being developed for prophylaxis of renal allograft rejection in recipients of kidney transplants.
VEL-101, a pegylated monoclonal antibody fragment CD28 antagonist, selectively blunts CD28 co-stimulation while sparing the CTLA-4 co-inhibitory signal.
